12:00 AM
Dec 07, 2009
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Vioxx rofecoxib: Post-marketing study data

Pooled data from 20,152 patients in a retrospective analysis of 30 placebo-controlled trials showed a significantly increased cardiovascular risk associated with Vioxx compared with placebo as of June 2001, nearly 3 years before Merck withdrew...

Read the full 152 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >